Technologies

Aliophen-XP is a highly concentrated polyphenolic composition derived from Aliophen®, a patented formulation based on malt and hops (Patent No. 102017000096298). Developed to enhance the original formulation, Aliophen-XP is produced through a specialized process that removes components potentially interfering with the biological activity of the bioactive compounds naturally extracted from malt and hops.

The procedure enables the fabrication of nanocomposite membranes filled with suitable amounts of exfoliated bidimensional crystals. These are obtained with an advanced wet-jet milling technique, which provides desired thickness and lateral size of nanofillers through the pulverization and colloidal homogenization of bulk nanomaterials. The bidimensional crystals are dispersed in fluids and suitably delivered inside polymeric matrixes exhibiting a singular morphology.

This invention comprises an interrogation and readout differential method for chemical sensors based on Surface Plasmon Resonances (SPR). The integration of the SPR sensing unit (chip or other), as intermediate reflecting element of a Fabry-Perot (FP) optical resonator, is the starting point for the application of this method.

Plants can compete favorably with traditional expression systems (mammalian cells, yeasts or bacteria) to produce recombinant proteins/peptides of pharmaceutical/industrial/agrifood interest. This technology names “Plant Molecular Farming”. The CNR-IBBA research team offers the study of new strategies for the expression and optimization of recombinant proteins/peptides in plant-based systems (plant tissues, transgenic plants, plant cell culture). Our pipeline is based on the following modules:

Currently, liposomes (artificially synthesised vesicles) are widely used as carriers for a variety of molecules in the cosmetic and pharmaceutical industries. In the clinical applications, for instance, they are employed to encapsulate a range of substances, such as antibiotics, proteins, genetic material, vitamins and anti-cancer drugs.